Chemicals & Pharmaceuticals

Our firm has been advising and representing French and foreign players in the chemical and pharmaceutical sectors for many years and has extensive experience handling both legal and arbitral proceedings in this area.

Our recent track record

  • Representing a French chemical group in a dispute concerning the payment of costs related to works requested by French Public Authorities for a storage unit for toxic products.
  • Representing one of the major American chemical companies in arbitration prior to litigation initiated in connection with the enforcement of an environmental liability guarantee relating to the sale of a production unit.
  • Representing a French chemical group in an ICC arbitration concerning the failure to achieve guaranteed performance of a phosphate production plant in the Middle East.
  • Representing a pharmaceutical company in a commercial dispute relating to the breach of a licence agreement for the production of vaccines.
  • Representing a group of Australian pharmaceutical companies, specialising in the distribution of food supplements, in UNCITRAL proceedings against a Canadian company in relation to a breach of a distribution agreement.
  • Representing a French pharmaceutical company in ICC arbitral proceedings against an American company, relating to a contractual dispute and the payment of an earn-out.
  • Representing an Algerian commercial agent in ICC arbitral proceedings against a world leader in the pharmaceutical industry, relating to non-payment of commissions and wrongful termination of the consultancy contract.
  • Representing a company manufacturing medical equipment in a dispute brought before the Commercial Court of Paris, concerning the termination without notice of established commercial relations with a distributor in North Africa.
  • Representing a group of majority shareholders in an ICC arbitration concerning the breach of a shareholders’ agreement relating to the governance of a chemical group in West Africa.
  • Representing a French pharmaceutical company holding a licence to manufacture drugs for orphan diseases against their distributor regarding the termination of their distribution contract in the United States of America due to the non-achievement of sales targets.

Our news

We regularly publish articles and speak at professional conferences on this area of expertise.


Inscrivez-vous à notre newsletter.


Subscribe to our newsletter.